<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Performance of omalizumab in patients with mast cell-mediated angioedema with and without wheals

Simple item page
dc.contributor.authorvan der Kamp, Sara
dc.contributor.authorSoegiharto, Reineke
dc.contributor.authorSorensen, Jennifer Astrup
dc.contributor.authorDemir, Ferhan Bulut
dc.contributor.authorPorras, Nasser Mohammad
dc.contributor.authorMatsuo, Yoshimi
dc.contributor.authorKiefer, Lea
dc.contributor.authorKnulst, Andre C.
dc.contributor.authorMaurer, Marcus
dc.contributor.authorRitchie, Carla
dc.contributor.authorRudenko, Michael
dc.contributor.authorKocaturk, Emek
dc.contributor.authorCriado, Roberta F. J.
dc.contributor.authorGregoriou, Stamatios
dc.contributor.authorBobylev, Tatjana
dc.contributor.authorKleinheinz, Andreas
dc.contributor.authorTakahagi, Shunsuke
dc.contributor.authorHide, Michihiro
dc.contributor.authorGimenez-Arnau, Ana M.
dc.contributor.authorSalman, Andac
dc.contributor.authorKara, Rabia O.
dc.contributor.authorDikicier, Bahar Sevimli
dc.contributor.authorvan Doorn, Martijn B. A.
dc.contributor.authorThomsen, Simon F.
dc.contributor.authorvan den Reek, Juul M. P. A.
dc.contributor.authorRockmann, Heike
dc.date.accessioned2026-11-05T11:08:43Z
dc.date.issued2026
dc.description.issue6
dc.description.pages1457-1460
dc.description.sponsorshipThis study is an extension of an initial project partially funded by Novartis Pharma B.V. (https://doi.org/10.1001/jamadermatol.2024.2056) , which had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manu-script; and decision to submit the manuscript for publication.
dc.description.volume14
dc.identifier.doi10.1016/j.jaip.2026.03.004
dc.identifier.issn2213-2198
dc.identifier.issn2213-2201
dc.identifier.urihttps://doi.org/10.1016/j.jaip.2026.03.004
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/11568
dc.identifier.wosWOS:001795403200001
dc.language.isoen
dc.publisherELSEVIER
dc.relation.fundingNovartis Pharma B.V.
dc.relation.hasversion10.1016/j.jaip.2026.03.004
dc.relation.ispartofJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
dc.subjectURTICARIA
dc.subjectAllergy
dc.subjectImmunology
dc.titlePerformance of omalizumab in patients with mast cell-mediated angioedema with and without wheals
dc.typeLetter
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.endPage1460
oaire.citation.issue6
oaire.citation.startPage1457
oaire.citation.volume14
person.identifier.orcid0000-0003-2801-0959
person.identifier.ridABD-8447-2020
person.identifier.ridO-8624-2015
person.identifier.ridLUZ-0464-2024
person.identifier.ridC-4725-2019
person.identifier.ridAAB-1203-2020
person.identifier.ridHPG-4394-2023
person.identifier.ridAFR-2739-2022
person.identifier.ridH-6587-2019
person.identifier.ridH-9583-2015

Files

Collections

WOS